CYP3A7 Activators
CYP3A7 Activators belong to a specialized category of chemical compounds designed to modulate the activity of the cytochrome P450 3A7 enzyme (CYP3A7). Cytochrome P450 enzymes, including CYP3A7, are a superfamily of heme-containing proteins that play a pivotal role in the metabolism of endogenous and exogenous compounds within the human body. CYP3A7, in particular, is a member of the CYP3A subfamily and is predominantly expressed in fetal liver tissues, where it contributes to the metabolic transformation of various molecules. While CYP3A7 is predominantly a fetal enzyme, it can persist into adulthood in some individuals and can have distinct substrate specificity compared to other CYP3A isoforms.
CYP3A7 Activators are compounds engineered to interact with CYP3A7 and influence its enzymatic activity. These activators can either enhance or inhibit CYP3A7's ability to metabolize specific substrates, depending on their chemical structure and mode of action. By targeting CYP3A7, these compounds provide researchers with a tool to investigate the role of CYP3A7 in the biotransformation of various compounds, including drugs, xenobiotics, and endogenous molecules, and to explore how its activity may contribute to developmental processes or disease states. The study of CYP3A7 Activators is vital for advancing our understanding of the complex metabolic pathways governed by cytochrome P450 enzymes and their potential impact on drug metabolism, toxicology, and developmental biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin is a potent inducer of CYP3A7. It enhances enzyme activity by binding to the pregnane X receptor (PXR), which leads to increased transcription of CYP3A7. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone, a synthetic glucocorticoid, upregulates CYP3A7 expression through glucocorticoid receptor-mediated pathways, leading to increased enzymatic activity. | ||||||
Carbamazepine | 298-46-4 | sc-202518 sc-202518A | 1 g 5 g | $33.00 $71.00 | 5 | |
Carbamazepine is an inducer of CYP3A7, enhancing its activity by activating PXR and CAR pathways, which upregulates the enzyme's expression. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a thiazolidinedione, induces CYP3A7 expression through PPARγ activation, leading to increased enzymatic activity. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
Troglitazone, another thiazolidinedione, induces CYP3A7 expression by activating PPARγ, enhancing the enzyme's metabolic capacity. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Although primarily a CYP3A inhibitor, ritonavir can paradoxically induce CYP3A7 expression at certain concentrations through PXR activation. | ||||||
Efavirenz | 154598-52-4 | sc-207612 | 10 mg | $171.00 | 3 | |
Efavirenz induces CYP3A7 expression by acting on PXR and CAR receptors, resulting in increased enzyme activity. | ||||||
Nevirapine | 129618-40-2 | sc-208092 | 5 mg | $99.00 | 5 | |
Nevirapine activates CYP3A7 by inducing its expression via the PXR pathway, enhancing metabolic processes catalyzed by the enzyme. | ||||||
5-Pregnen-3β-ol-20-one-16α-carbonitrile | 1434-54-4 | sc-227010 | 50 mg | $69.00 | 3 | |
This compound selectively activates CYP3A7 by binding to PXR, leading to an increase in the enzyme's expression and activity. | ||||||